Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522621 | 1.00 | KMT2A (0.63) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL521952 | 0.87 | KMT2A (0.64) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL521951 | 0.87 | KMT2A (0.64) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL522144 | 0.86 | KMT2A (0.63) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL522145 | 0.86 | KMT2A (0.63) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL522318 | 0.86 | KMT2A (0.74) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL522317 | 0.86 | KMT2A (0.74) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL10033925 | 0.84 | KMT2A (0.72) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL522664 | 0.84 | KMT2A (0.60) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL522665 | 0.84 | KMT2A (0.60) | KMT2AMEN1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029197-A1 | Method for Preparing Sulfur-Containing Compounds | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2012-02-02 | — | — | US | claimed |
| EP-2376444-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | The Royal College of Surgeons in Ireland (IE) | 2011-10-19 | — | — | EP | claimed |
| WO-2010066450-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2010-06-17 | — | — | WO | claimed |
| EP-2376444-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | The Royal College of Surgeons in Ireland (IE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066450-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196456-A1 | A method for preparing sulfur-containing compounds | Royal College of Surgeons in Ireland (IE) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029197-A1 | Method for Preparing Sulfur-Containing Compounds | SULT1E1, SULT1A1, TST | KMT2A 1785/4885MEN1 3925/4885MAPT 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.